26 May 2013
Keywords: alexion, completes, phase, study, 5g1, pharmaceuticals, usa
Article | 07 January 2002
Alexion Pharmaceuticals of the USA says its humanized monoclonalantibody C5 complement inhibitor, 5G1.1, appears to be well-tolerated
and to be ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 January 2002
24 May 2013
© 2013 thepharmaletter.com